66 related articles for article (PubMed ID: 9816305)
1. Anticarcinoma activity of a novel drug, 3-ethyl-3'-methyl-thiatelluracarbocyanine iodide (Te), a tellurium-containing cyanine targeted at mitochondria.
Sun X; Wong JR; Song K; Chen LB
Clin Cancer Res; 1996 Aug; 2(8):1335-40. PubMed ID: 9816305
[TBL] [Abstract][Full Text] [Related]
2. AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity.
Sun X; Wong JR; Song K; Hu J; Garlid KD; Chen LB
Cancer Res; 1994 Mar; 54(6):1465-71. PubMed ID: 8137249
[TBL] [Abstract][Full Text] [Related]
3. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation.
Weiss MJ; Wong JR; Ha CS; Bleday R; Salem RR; Steele GD; Chen LB
Proc Natl Acad Sci U S A; 1987 Aug; 84(15):5444-8. PubMed ID: 3474661
[TBL] [Abstract][Full Text] [Related]
4. Anticarcinoma activity of rhodamine 123 against a murine renal adenocarcinoma.
Herr HW; Huffman JL; Huryk R; Heston WD; Melamed MR; Whitmore WF
Cancer Res; 1988 Apr; 48(8):2061-3. PubMed ID: 3349477
[TBL] [Abstract][Full Text] [Related]
5. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation.
Koya K; Li Y; Wang H; Ukai T; Tatsuta N; Kawakami M; Shishido ; Chen LB
Cancer Res; 1996 Feb; 56(3):538-43. PubMed ID: 8564968
[TBL] [Abstract][Full Text] [Related]
6. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI
Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645
[TBL] [Abstract][Full Text] [Related]
8. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
Narla RK; Chen CL; Dong Y; Uckun FM
Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
[TBL] [Abstract][Full Text] [Related]
9. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
[TBL] [Abstract][Full Text] [Related]
10. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols.
Hickey JL; Ruhayel RA; Barnard PJ; Baker MV; Berners-Price SJ; Filipovska A
J Am Chem Soc; 2008 Sep; 130(38):12570-1. PubMed ID: 18729360
[TBL] [Abstract][Full Text] [Related]
13. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
16. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
[TBL] [Abstract][Full Text] [Related]
18. Potential new antitumor agents from an innovative combination of camphorato, a ramification of traditional Chinese medicine, with a platinum moiety.
Wang L; Gou S; Chen Y; Liu Y
Bioorg Med Chem Lett; 2005 Jul; 15(14):3417-22. PubMed ID: 15953727
[TBL] [Abstract][Full Text] [Related]
19. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
20. Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors.
Park R; Chang CC; Liang YC; Chung Y; Henry RA; Lin E; Mold DE; Huang RC
Clin Cancer Res; 2005 Jun; 11(12):4601-9. PubMed ID: 15958646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
